Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Clover Health Investments, Corp. (CLOV)

4.3100 -0.1500 (-3.36%)
At close: November 2 at 4:00:01 PM EST
4.3400 +0.0300 (+0.70%)
Pre-Market: 7:03:15 AM EST
Trade CLOV on Coinbase
CLOV Q3 2026 earnings call
November 4, 2026 at 5 PM EST
Chart Range Bar
Loading chart for CLOV

What's happening with CLOV?

14m ago
Powered by Yahoo Scout

Clover Health enters November with a 5-Star Medicare Advantage PPO rating for 2027, strong membership growth, and renewed analyst coverage. The company is scheduled to report third-quarter results on November 4, while investors will watch whether medical-cost trends and cohort profitability support the bullish growth narrative.

Powered by Yahoo Scout
  • Previous Close 4.4600
  • Open 4.5300
  • Bid 3.2300 x 200
  • Ask 4.3200 x 100
  • Day's Range 4.2726 - 4.5324
  • 52 Week Range 1.5800 - 5.5900
  • Volume 5,005,122
  • Avg. Volume 4,222,815
  • Market Cap (intraday) 2.289B
  • Beta (5Y Monthly) 2.48
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0500
  • Earnings Date Nov 4, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 5.50
  • Motley Fool Rating Bullish

Clover Health Investments, Corp. provides medicare advantage plans in the United States. The company offers preferred provider organization and health maintenance organization plans to medicare-eligible individuals. It also operates Clover Assistant, a software platform for physicians to detect, identify, and manage chronic diseases. The company was founded in 2014 and is based in Wilmington, Delaware.

www.cloverhealth.com

724

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Healthcare Plans

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

CLOV
83.40%
S&P 500 (^GSPC)
10.17%

1-Year Return

CLOV
22.10%
S&P 500 (^GSPC)
10.25%

3-Year Return

CLOV
326.73%
S&P 500 (^GSPC)
74.66%

5-Year Return

CLOV
43.29%
S&P 500 (^GSPC)
62.86%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 743.17M
Earnings 28M
Profit Margin 3.77%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
200M
400M
600M
-10.0%
-5.0%
0.0%

Analyst Insights

View More

Analyst Price Targets

5.00
5.50 Average
4.3100 Current
6.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/28/2026
Analyst Needham
Rating Action Initiated
Rating Buy
Price Action Announces
Price Target 6

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -0.74%

  • Return on Assets (ttm)

    -1.77%

  • Return on Equity (ttm)

    -5.10%

  • Revenue (ttm)

    2.48B

  • Net Income Avi to Common (ttm)

    -18.36M

  • Diluted EPS (ttm)

    -0.0500

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    243.1M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    69.05M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: